该文报道1例静脉注射免疫球蛋白（intravenous immunogloblin，IVIG）无应答不完全性川崎病患儿。1岁女性患儿，表现为发热、皮疹、指端脱皮、冠状动脉扩张，给予第一剂IVIG治疗结束36 h后仍发热，再次给予第二剂IVIG治疗后体温恢复正常，出院1个月后随访冠状动脉内径恢复正常。该文总结了IVIG无应答不完全性川崎病的诊治经验，以期减少冠状动脉损害的发生。
Abstract
This article reports a case of incomplete Kawasaki disease with no response to intravenous immunoglobulin (IVIG). A girl, aged 1 year, had the symptoms of fever, rash, finger desquamation, and coronary artery ectasia. She still had fever at 36 hours after the first dose of IVIG treatment, and her temperature returned to normal after the second dose of IVIG treatment. The follow-up after 1 month showed that the coronary artery diameter returned to normal. This article summarizes the experience in the treatment of incomplete Kawasaki disease with no response to IVIG in order to reduce the incidence of coronary artery damage.
关键词
不完全性川崎病 /
静脉注射免疫球蛋白 /
无应答 /
冠状动脉损害 /
幼儿
Key words
Incomplete Kawasaki disease /
Intravenous immunoglobulin /
No response /
Coronary artery damage /
Infant
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
2 Yang TJ, Lin MT, Lu CY, et al. The prevention of coronary arterial abnormalities in Kawasaki disease: a meta-analysis of the corticosteroid effectiveness[J]. J Microbiol Immunol Infect, 2018, 51(3): 321-331. PMID: 28927685. DOI: 10.1016/j.jmii.2017.08.012.
3 Tajima M, Shiozawa Y, Kagawa J. Early appearance of principal symptoms of Kawasaki disease is a risk factor for intravenous immunoglobulin resistance[J]. Pediatr Cardiol, 2015, 36(6): 1159-1165. PMID: 25753685. DOI: 10.1007/s00246-015-1136-2.
4 Lin MC, Lai MS, Jan SL, et al. Epidemiologic features of Kawasaki disease in acute stages in Taiwan, 1997-2010: effect of different case definitions in claims data analysis[J]. J Chin Med Assoc, 2015, 78(2): 121-126. PMID: 25636582. PMCID: PMC7105041. DOI: 10.1016/j.jcma.2014.03.009.
5 Muta H, Ishii M, Yashiro M, et al. Late intravenous immunoglobulin treatment in patients with Kawasaki disease[J]. Pediatrics, 2012, 129(2): e291-e297. PMID: 22250032. DOI: 10.1542/peds.2011-1704.
6 中华医学会儿科学分会心血管学组, 中华医学会儿科学分会风湿学组, 中华医学会儿科学分会免疫学组, 等. 川崎病诊断和急性期治疗专家共识[J]. 中华儿科杂志, 2022, 60(1): 6-13. PMID: 34986616. DOI: 10.3760/cma.j.cn112140-20211018-00879.
7 Manlhiot C, O'Shea S, Bernknopf B, et al. Epidemiology of Kawasaki disease in Canada 2004 to 2014: comparison of surveillance using administrative data vs periodic medical record review[J]. Can J Cardiol, 2018, 34(3): 303-309. PMID: 29395706. DOI: 10.1016/j.cjca.2017.12.009.
8 Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J]. Circ J, 2020, 84(8): 1348-1407. PMID: 32641591. DOI: 10.1253/circj.CJ-19-1094.
9 Friedman KG, Jone PN. Update on the management of Kawasaki disease[J]. Pediatr Clin North Am, 2020, 67(5): 811-819. PMID: 32888683. DOI: 10.1016/j.pcl.2020.06.002.
10 Soni PR, Noval Rivas M, Arditi M. A comprehensive update on Kawasaki disease vasculitis and myocarditis[J]. Curr Rheumatol Rep, 2020, 22(2): 6. PMID: 32020498. DOI: 10.1007/s11926-020-0882-1.
PDF(403 KB)
